Low Testosterone and Heart Disease — The Hidden Connection

Why Doctors Are Finally Taking Low Testosterone Seriously as a Heart Risk

The relationship between testosterone and heart disease has been debated for 30 years. The early fears — that testosterone increased cardiac risk — came from studies of supraphysiological doses used in sport and bodybuilding. These fears were reasonable but critically misapplied to therapeutic replacement in hypogonadal men, where the goal is to restore levels to the normal physiological range, not exceed it.

The evidence has shifted dramatically since 2010. Multiple large studies, including the landmark TRAVERSE trial (2023) — the largest cardiovascular outcomes trial for testosterone replacement therapy — confirmed that TRT does not increase cardiac risk in men with documented hypogonadism. The study enrolled over 5,000 high-risk men and followed them for years. The conclusion was unambiguous: appropriately prescribed TRT is cardiovascularly safe.

Meanwhile, the evidence that low testosterone itself is harmful to the heart has become overwhelming. Low T is now classified as an independent predictor of metabolic syndrome, type 2 diabetes, cardiovascular events, and all-cause mortality. This is not a fringe position — it is the current consensus position of the European Association of Urology and the American Urological Association.

The Indian context makes this particularly urgent. Indian men develop cardiovascular disease on average 10 years earlier than Western men, and our rates of testosterone deficiency are poorly studied — but almost certainly high, given the epidemic of visceral obesity, sedentary lifestyles, and type 2 diabetes in the country. The intersection of these risk factors creates a population of men who are quietly accumulating cardiovascular risk without any hormonal assessment.

At Gini, Dr. Nitin Aggarwal and Dr. Anil Bhansali screen every man who presents with fatigue, erectile dysfunction, or metabolic syndrome for testosterone deficiency as a standard protocol. This is not routine elsewhere in North India. It should be. A condition that affects 20–30% of men over 45 and independently raises cardiac risk deserves the same systematic screening as blood pressure or cholesterol.

What the Research Shows — Low T and Cardiovascular Events

The research linking low testosterone to cardiovascular disease is now extensive and consistent. A 2014 meta-analysis of 70 studies involving 3,600 men found that men with low testosterone had:

• 88% higher risk of metabolic syndrome
• 2.5× higher risk of type 2 diabetes
• 35% higher risk of cardiovascular events
• 25% higher risk of all-cause mortality

A 2019 European Heart Journal study found that men with low free testosterone had a 40% higher rate of major adverse cardiac events (MACE) over 10 years compared to men with normal levels — even after adjusting for age, blood pressure, diabetes, and smoking status. Low T is an independent risk factor, not just a marker of other problems.

The mechanism is well understood. Testosterone promotes lean muscle mass and reduces visceral fat — the metabolically active abdominal fat that drives insulin resistance, dyslipidaemia, and hypertension. When testosterone falls, visceral fat accumulates. LDL rises. HDL falls. Blood pressure increases. Insulin sensitivity decreases. These are the building blocks of cardiovascular disease, and testosterone deficiency accelerates all of them simultaneously.

In the Indian context, this matters particularly because Indian men have a genetic predisposition to visceral fat deposition even at lower BMIs. A man with a BMI of 26 — technically "normal" by Western standards — may have significant visceral adiposity by Indian standards. Low testosterone amplifies this predisposition, creating a compounding cycle: low T increases visceral fat, visceral fat converts testosterone to oestrogen via aromatase, and further testosterone falls.

The interaction between testosterone, diabetes, and cardiovascular risk is precisely why Gini's integrated endocrinology-urology approach is clinically important. These conditions do not exist in separate organ systems — they are metabolically linked, and they must be assessed and treated together.

The ED–Heart Disease Connection — The Canary in the Coal Mine

Erectile dysfunction is the most underutilised cardiovascular screening tool in clinical medicine. This is not a provocative claim — it is the conclusion of three decades of vascular research and is now embedded in major cardiology guidelines.

Here is the anatomical reason. The penile arteries are the smallest arteries in the body — measuring 1–2mm in diameter. The coronary arteries are 3–4mm. Atherosclerosis — the plaque build-up that narrows arteries and causes heart attacks — affects the smallest arteries first. This means that vascular ED appears, on average, 3–5 years before the first cardiac event. ED from vascular disease is an early warning signal, not a consequence.

A landmark 2011 study in the Journal of the American College of Cardiology showed that men with new-onset ED at age 40–49 had a 50% probability of a major cardiac event within 5 years if they also had hypertension, dyslipidaemia, or diabetes. This is not a marginal statistical risk — this is the level of risk that cardiologists act on aggressively in other contexts.

The Princeton Consensus — now in its 4th edition and regarded as the gold standard framework for managing ED and cardiac risk together — recommends that all men presenting with new-onset ED should have a full cardiac risk assessment before being prescribed PDE5 inhibitors (Viagra, Cialis, etc.). Yet the reality in India is that most men with ED are handed a prescription and sent home. The opportunity to identify and intervene on cardiovascular disease at its earliest stage is missed entirely.

At Gini, every man presenting with ED receives: lipid profile, HbA1c, blood pressure assessment, Framingham cardiac risk scoring, and testosterone assessment. We do not manage ED as an isolated condition. We manage it as what it is: a vascular and hormonal condition that may be the earliest detectable sign of systemic cardiovascular disease.

How Testosterone Replacement Therapy Affects the Heart

The TRAVERSE trial (2023) is the most important study in this area. It enrolled 5,246 men with documented hypogonadism and pre-existing cardiovascular risk factors — precisely the highest-risk population in whom concerns about TRT were greatest. The result: testosterone replacement was non-inferior to placebo for major cardiovascular events. This is the highest level of evidence available, and it is reassuring.

Beyond safety, smaller randomised studies have shown that appropriately dosed TRT in hypogonadal men produces meaningful improvements in cardiovascular risk markers:

• LDL reduction of 5–10%
• HDL increase of 5%
• Blood pressure reduction of 3–5 mmHg
• Waist circumference reduction of 4–6 cm
• HbA1c reduction of 0.5–1.0 points in diabetic hypogonadal men

These are clinically meaningful effects. In the context of a man who is already managing hypertension, diabetes, and dyslipidaemia, improvements of this magnitude represent a real reduction in cardiovascular risk — not a marginal statistical benefit.

Important caveats apply. TRT must be monitored. The primary safety concern with TRT is haematocrit (red blood cell count) elevation — testosterone stimulates red blood cell production, and if haematocrit rises too high, it increases blood viscosity and clotting risk. This is managed with 3-monthly haematocrit monitoring and dose adjustment. It is a manageable side effect, not a reason to withhold treatment from men who need it.

TRT should not be started in men with: a cardiac event within the past 6 months, uncontrolled heart failure, active polycythaemia, haematocrit above 54%, or untreated severe obstructive sleep apnoea. At Gini, all TRT patients undergo cardiac risk assessment before initiation and are monitored with a structured 3-monthly protocol throughout treatment.

Who Should Be Screened — The Gini Men's Health Protocol

Dr. Nitin Aggarwal and Dr. Anil Bhansali have developed a shared-care protocol for men's cardiovascular-hormonal health at Gini Advanced Care Hospital. The protocol is designed to identify testosterone deficiency early — before it contributes to irreversible cardiovascular damage.

Any man over 35 with two or more of the following should be screened:

• Fatigue not explained by lifestyle or sleep alone
• Erectile dysfunction or significantly reduced libido
• Waist circumference above 90cm
• Type 2 diabetes or pre-diabetes (HbA1c above 5.7%)
• Hypertension requiring medication
• Family history of heart disease before age 60
• Total cholesterol above 5.0 mmol/L despite treatment

The screening blood panel:

• Morning total testosterone (must be drawn before 10am, fasting)
• Free testosterone + SHBG (sex hormone binding globulin)
• HbA1c
• Fasting lipid profile
• LH + FSH (to distinguish primary from secondary hypogonadism)
• Prolactin
• Full blood count

This panel costs approximately ₹4,000–6,000 and provides a complete picture of hormonal and metabolic health. The AndroScore assessment at /androscore is a free online pre-screening tool that takes 3 minutes. Men who score Amber or below are recommended for the full blood panel. It is a practical first step before committing to a clinical consultation.

What to Do If You Think Your Testosterone Is Low

The path from concern to diagnosis to treatment is straightforward at Gini. Here is the exact process:

1. Step 1: Take the AndroScore. The 5-domain assessment takes 3 minutes and gives you a baseline score across testosterone symptoms, metabolic health, sexual function, urological health, and fertility. Men who score below 35 in any domain are flagged for clinical review.
2. Step 2: Book a morning testosterone blood test. Before 10am, fasting. Testosterone follows a circadian rhythm — levels are at their daily peak in the early morning and fall by 20–25% by afternoon. An afternoon result that appears "borderline" may actually be significantly low when corrected for time of day.
3. Step 3: Bring the results to Dr. Nitin Aggarwal or Dr. Anil Bhansali at Gini. A single result below 300 ng/dL with clinical symptoms is sufficient to begin the formal diagnostic process. Two results below 300 ng/dL on separate mornings confirms hypogonadism.
4. Step 4: Full clinical assessment. History, examination, full blood panel as outlined above, cardiac risk scoring. This is a clinical assessment — it includes physical examination for signs of hypogonadism, testicular volume assessment, and baseline cardiovascular risk stratification.
5. Step 5: Individualised protocol. If TRT is indicated — appropriate formulation, starting dose, monitoring schedule. If lifestyle optimisation first — structured programme with specific targets and a retest timeline. If secondary causes are found (pituitary, thyroid) — targeted investigation and referral.

The full consultation and blood panel interpretation at Gini costs ₹3,500 through the Men's Health Programme. This is not a lifestyle wellness consultation — it is a clinical assessment by a specialist urologist and endocrinologist working together, using evidence-based protocols.